Premium
Letter: infliximab de‐escalation based on trough levels in patients with inflammatory bowel disease
Author(s) -
Paul S.,
Roblin X.,
PeyrinBiroulet L.
Publication year - 2015
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.13335
Subject(s) - medicine , infliximab , discontinuation , de escalation , inflammatory bowel disease , faecal calprotectin , gastroenterology , trough level , adalimumab , calprotectin , surgery , tumor necrosis factor alpha , disease , transplantation , tacrolimus
International audienc